British luxury automaker Aston Martin said on Wednesday that it will cut up to 20% of its workforce as tariff and regulatory headwinds along with a challenging market backdrop weigh on the business. The company said the cuts will result in an annualized savings of about 40 million pounds ($54 million), most of which will occur this year. The company employs about 3,000 workers.Aston Martin didn't specify when the cuts would occur this year, and they include the 5% workforce reduction the company announced l ...

Financial Performance - LivaNova reported a total revenue of $1.2 billion for the fiscal year ended December 31, 2023, representing a 10% increase compared to the previous year[7]. - The company achieved a gross margin of 65%, up from 62% in 2022, indicating improved operational efficiency[7]. - LivaNova's net revenue for the year ended December 31, 2025, was distributed as follows: 53% from the U.S., 19% from Europe, and 28% from the Rest of the World[48]. - LivaNova reported a total revenue of $1.2 billion for the year ended December 31, 2022, representing a 10% increase compared to the previous year[16]. - The company reported a net income of $150 million for 2022, reflecting a 5% increase from the previous year[16]. Research and Development - LivaNova's R&D expenses increased to $150 million, accounting for 12.5% of total revenue, as the company focuses on new product development and innovation[7]. - LivaNova is investing $100 million in R&D for new product development, including advancements in VNS Therapy and new Cardiopulmonary devices[16]. - LivaNova's R&D investment emphasizes technological advancements, including AI and software improvements, to maintain market leadership[45]. - LivaNova's R&D investment focuses on product design, technology, AI, and clinical study programs to maintain market leadership and address unmet patient needs[45]. - In June 2025, LivaNova completed the CORE-VNS study, reporting 36-month data showing reductions in seizure frequency among individuals with DRE treated with VNS Therapy[36]. - In 2024, preliminary results from the RECOVER clinical study for unipolar depression did not meet primary endpoints but showed significant improvements in secondary endpoints related to quality of life[40]. Market Strategy and Expansion - The company plans to expand its market presence in Asia, targeting a 20% growth in that region by 2025[7]. - LivaNova's market expansion strategy includes entering three new international markets by the end of 2024, targeting a 10% market share in each[16]. - LivaNova has initiated a restructuring plan aimed at enhancing focus on its core Cardiopulmonary and Neuromodulation segments, expected to yield $50 million in annual savings[7]. - The company plans to initiate a restructuring plan in Q1 2024 to enhance focus on its core segments, aiming for a 20% reduction in operational costs by 2025[16]. - LivaNova's commitment to sustainability includes a goal to reduce carbon emissions by 30% by 2025, aligning with global environmental standards[7]. Product Development and Innovation - User data showed a 15% increase in the adoption of VNS Therapy systems, with over 50,000 patients treated globally[7]. - LivaNova's new product launch, the Hemolung Respiratory Assist System, is projected to generate $100 million in revenue within the first two years of its release[7]. - The Cardiopulmonary segment includes products such as HLMs, oxygenators, and autotransfusion systems, which are essential for various heart-related medical procedures[25][26]. - The Neuromodulation segment focuses on devices for treating drug-resistant epilepsy (DRE) and treatment-resistant depression (DTD), including the VNS Therapy System[31][33]. - The company received FDA approval for the aura6000 System for obstructive sleep apnea (OSA) and announced that the OSPREY clinical trial met its primary endpoints for efficacy and safety in 2024[42][43]. Competitive Landscape - The company faces increasing competitive pressure leading to downward pricing trends as hospitals seek to reduce costs through centralized purchasing and limiting vendor participation[51]. - LivaNova's primary competitors in the Cardiopulmonary and Neuromodulation product groups include Terumo Medical Corporation, Medtronic plc, and Haemonetics Corporation[54]. Regulatory Compliance - LivaNova must comply with extensive government regulations for product approval, including the FDA's 510(k) clearance and PMA processes, which can be costly and time-consuming[57]. - The EU's MDR requires compliance by December 2027 or 2028, with penalties for non-compliance potentially including fines and revocation of marketing authorization[58]. - Under GDPR, LivaNova faces potential fines of up to €20 million ($23.5 million) or 4% of total worldwide annual net revenue for non-compliance with data protection regulations[65]. - The company is subject to various environmental regulations that may increase compliance costs and expose it to liabilities related to hazardous substances[66]. - LivaNova's operations are governed by anti-corruption laws such as the FCPA and the UK Bribery Act, which could lead to civil or criminal sanctions if violated[68]. Employee Engagement and Corporate Culture - The company had approximately 3,300 employees worldwide as of December 31, 2025, representing over 80 nationalities[82]. - Over 94% of employees participated in the most recent engagement survey, indicating strong employee engagement and satisfaction[85]. - LivaNova's proactive talent acquisition strategies and competitive compensation have been significant drivers of the company's success[83]. - The company is committed to maintaining a diverse and inclusive workplace, supporting various employee affinity initiatives[90]. - LivaNova's performance management process aims to enhance employee skills and capabilities through regular feedback and training[86]. Economic and Market Conditions - The company continues to monitor economic developments, including inflation and raw material costs, which may impact production costs and pricing behavior[71]. - LivaNova is subject to various healthcare regulations, including the Anti-Kickback Statute and False Claims Act, which impose significant compliance costs[79]. - The company employs a multifactorial approach to price setting to reflect the value of its specialized products while providing cost efficiencies to customers[71]. - LivaNova's products are subject to approval from third-party payers for coverage and reimbursement, impacting demand for new devices[70].

For the quarter ended December 2025, LivaNova (LIVN) reported revenue of $360.9 million, up 12.2% over the same period last year. EPS came in at $0.86, compared to $0.81 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $350.93 million, representing a surprise of +2.84%. The company delivered an EPS surprise of +7.06%, with the consensus EPS estimate being $0.80.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...

Performance in 2025 was characterized by the third consecutive year of double-digit organic revenue growth, driven by the Essence heart-lung machine (HLM) rollout and market share gains in cardiopulmonary consumables. The cardiopulmonary segment's growth is being fueled by a global upgrade cycle, with Essence representing 55% of HLM units in 2025 and targeted to reach 80% of new placements by 2026. Management attributed epilepsy growth to strong commercial execution and the impact of the CORE VNS stud ...

Core Insights - LivaNova PLC is a key player in the medical device industry, focusing on Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments, with a commitment to innovative therapeutic solutions globally [1] Financial Performance - LivaNova reported fourth-quarter revenue of $360.9 million, reflecting a 12.1% increase from the previous year, indicating strong financial performance [3][6] - The U.S. GAAP diluted earnings per share for the fourth quarter was $0.56, further supporting the positive financial outlook [3] Price Target Trends - The consensus price target for LivaNova's stock has risen to an average of $85, up from $74.33 three months ago and $69.63 a year ago, indicating growing analyst confidence [2][6] - Analyst firm Robert W. Baird has set a price target of $75, aligning with the company's strong financial performance and strategic initiatives [5] Strategic Initiatives - LivaNova's collaboration with Verily to capture clinical biomarkers of depression is expected to enhance its product offerings and market position [4][6] - The company's presentation at the American Epilepsy Society Annual Meeting underscores its commitment to advancing medical technology [4][6]

LivaNova (NasdaqGS:LIVN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsAhmet Tezel - Chief Innovation OfficerAlex Shvartsburg - CFOAnthony Petrone - Managing Director and Equity ResearchBrianna Gotlin - Vice President of Investor RelationsJohn McAulay - Associate VPVladimir Makatsaria - CEOConference Call ParticipantsAdam Maeder - Managing Director and Senior Research AnalystBrett Fishman - VP and Senior Equity Research AnalystDavid Rescott - Senior Research AnalystMichael Polark - ...

LivaNova (NasdaqGS:LIVN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsAhmet Tezel - Chief Innovation OfficerAlex Shvartsburg - CFOAnthony Petrone - Managing Director and Equity ResearchBrianna Gotlin - Vice President of Investor RelationsJohn McAulay - Associate VPVladimir Makatsaria - CEOConference Call ParticipantsAdam Maeder - Managing Director and Senior Research AnalystBrett Fishman - VP and Senior Equity Research AnalystDavid Rescott - Senior Research AnalystMichael Polark - ...

LivaNova (NasdaqGS:LIVN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker10Good day, ladies and gentlemen, and welcome to the LivaNova PLC fourth quarter and full year 2025 earnings conference call. My name is Emily, and I'll be coordinating your call today. After the presentation, you will have the opportunity to ask any questions, which you can do so by pressing star 1 on your telephone keypad. As a reminder, this conference call is being recorded. I would now like to introduce your host for to ...

Fourth-Quarter & Full-Year 2025 Earnings Update Safe Harbor Certain statements in this material, other than statements of historical or current fact, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distribut ...

EXHIBIT 99.1 reported fourth-quarter and full-year 2025 results and issued full-year 2026 guidance. Financial Summary and Highlights (1) Constant-currency percent change, organic revenue percent change, adjusted diluted earnings per share, and adjusted free cash flow are non-GAAP measures. Constant-currency percent change excludes the impact from fluctuations in the various currencies in which the Company operates as compared to reported percent change. Organic revenue percent change excludes the impact of ...